Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $119.27M by Medicaid between Jan 2018 and Dec 2024, across 624 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
BROOKLYN, NY 11206
BROOKLYN, NY 11206
33aNPI1467469023assigned 08/03/2006
33bProvider typeInternal Medicine Physician
28Total paid$119.27M
24GClaims2,827,758
24DCodes billed624
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#7 of 6,049
Median peer was paid$11K
This provider vs. median10,544×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 73,077 | $568K | |
| 2019 | 213,644 | $7.31M | |
| 2020 | 421,094 | $19.24M | |
| 2021 | 636,499 | $26.80M | |
| 2022 | 620,143 | $27.59M | |
| 2023 | 454,295 | $19.89M | |
| 2024incomplete | 409,006 | $17.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 97,080 | 90,734 | $14.05M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.6% | 158,992 | 135,529 | $11.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.4% | 69,774 | 64,122 | $11.22M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 6.5% | 11,189 | 9,546 | $7.77M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.9% | 71,281 | 62,936 | $5.81M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 3.6% | 37,086 | 27,368 | $4.29M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 18,781 | 17,664 | $2.92M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 44,485 | 39,220 | $2.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 13,419 | 12,722 | $2.21M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.8% | 32,956 | 29,275 | $2.17M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 1.5% | 11,335 | 7,601 | $1.82M |
| D0999 | Unspecified diagnostic procedure, by report | 1.4% | 10,854 | 10,610 | $1.73M |
612 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 10,757 | $1.69M |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 186,584 | $1.49M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 15,778 | $1.34M |
| S9485 | Crisis intervention mental health services, per diem | <1% | 1,059 | $1.19M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 16,422 | $1.17M |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 8,387 | $1.16M |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 10,404 | $1.11M |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 7,320 | $1.09M |
| 81412 | <1% | 617 | $963K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 29,216 | $867K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,137 | $820K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 8,464 | $817K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14,029 | $813K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 15,383 | $787K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 5,186 | $739K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 27,424 | $692K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 25,669 | $674K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,636 | $655K |
| 80053 | Comprehensive metabolic panel | <1% | 67,458 | $641K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 18,307 | $577K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 32,031 | $564K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,161 | $557K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,559 | $555K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,162 | $554K |
| 99442 | <1% | 10,514 | $548K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 792 | $542K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30,149 | $514K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,293 | $483K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,301 | $459K |
| 86480 | <1% | 7,842 | $459K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 3,667 | $447K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,052 | $442K |
| 87536 | <1% | 5,024 | $431K | |
| 76641 | <1% | 4,158 | $406K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 479 | $393K |
| 80061 | Lipid panel | <1% | 37,208 | $380K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,988 | $367K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 466 | $365K |
| 90461 | <1% | 12,013 | $351K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 4,068 | $344K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 17,126 | $344K |
| 85027 | <1% | 101,496 | $339K | |
| 59025 | Fetal non-stress test | <1% | 3,664 | $338K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,084 | $329K |
| 86360 | <1% | 6,981 | $322K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,976 | $310K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,795 | $306K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 4,185 | $300K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 43,987 | $300K |
| 99443 | <1% | 3,897 | $284K | |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 1,651 | $282K |
| 76818 | <1% | 3,415 | $279K | |
| H0037 | Community psychiatric supportive treatment program, per diem | <1% | 270 | $278K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 31,630 | $276K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,801 | $272K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,573 | $261K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,856 | $261K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,300 | $261K |
| 99441 | <1% | 9,758 | $256K | |
| 86703 | <1% | 20,385 | $255K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,676 | $252K |
| 86359 | <1% | 7,073 | $251K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,435 | $250K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,567 | $248K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 9,111 | $247K |
| 70486 | <1% | 1,798 | $245K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,008 | $236K |
| 76830 | Ultrasound, transvaginal | <1% | 2,683 | $235K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 8,910 | $233K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,209 | $225K |
| 0002A | <1% | 7,419 | $223K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 27,119 | $220K |
| 90750 | <1% | 2,673 | $214K | |
| 82962 | <1% | 42,867 | $213K | |
| 0001A | <1% | 7,620 | $211K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,383 | $209K |
| 90677 | <1% | 1,792 | $202K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,902 | $201K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,676 | $193K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,753 | $187K |
| 93970 | <1% | 1,106 | $181K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,910 | $177K |
| 11721 | <1% | 5,614 | $176K | |
| 76801 | <1% | 1,782 | $171K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 2,516 | $170K |
| 12001 | <1% | 813 | $169K | |
| 99205 | Prolong outpt/office vis | <1% | 922 | $164K |
| 86769 | <1% | 4,391 | $158K | |
| 86850 | <1% | 9,653 | $157K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 2,412 | $154K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,375 | $149K |
| 90697 | <1% | 1,780 | $149K | |
| 90715 | <1% | 6,449 | $148K | |
| 12011 | <1% | 735 | $148K | |
| 76770 | <1% | 1,155 | $148K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 317 | $147K |
| 99201 | <1% | 2,227 | $144K | |
| 97162 | <1% | 1,483 | $143K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,727 | $140K |
| 92015 | Determination of refractive state | <1% | 6,076 | $139K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 21,941 | $137K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,633 | $130K |
| 99381 | <1% | 1,373 | $128K | |
| 71045 | Radiologic examination, chest; single view | <1% | 16,020 | $128K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 5,926 | $127K |
| 77066 | Tomosynthesis, mammo | <1% | 816 | $122K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 184 | $121K |
| 86803 | <1% | 11,448 | $119K | |
| 83655 | <1% | 9,941 | $119K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 790 | $117K |
| D0120 | Dental checkup, returning patient | <1% | 11,439 | $117K |
| 96127 | <1% | 28,681 | $116K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 9,177 | $112K |
| D0140 | Limited oral evaluation - problem focused | <1% | 11,689 | $111K |
| 86780 | <1% | 10,167 | $110K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,675 | $109K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,105 | $109K |
| 90686 | <1% | 11,632 | $108K | |
| 90651 | <1% | 1,634 | $103K | |
| 92250 | <1% | 2,992 | $102K | |
| 80076 | <1% | 16,385 | $102K | |
| 90746 | <1% | 1,842 | $101K | |
| 77065 | Tomosynthesis, mammo | <1% | 843 | $101K |
| 86901 | <1% | 9,700 | $97K | |
| 73630 | <1% | 4,625 | $95K | |
| 71271 | <1% | 387 | $95K | |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | <1% | 502 | $83K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,395 | $83K |
| 90734 | <1% | 1,358 | $82K | |
| D1120 | Dental cleaning, child | <1% | 8,024 | $82K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,481 | $78K |
| 87535 | <1% | 2,284 | $78K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,735 | $75K |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 3,109 | $74K |
| 97010 | <1% | 9,401 | $74K | |
| 86900 | <1% | 9,684 | $73K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,806 | $73K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,663 | $71K |
| 71250 | <1% | 353 | $70K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,081 | $68K |
| 73564 | <1% | 2,489 | $67K | |
| 99385 | <1% | 862 | $67K | |
| 81001 | <1% | 33,740 | $67K | |
| D1110 | Prophylaxis - adult | <1% | 4,198 | $67K |
| 86706 | <1% | 7,801 | $65K | |
| 97802 | <1% | 2,649 | $65K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,216 | $63K |
| 10060 | <1% | 367 | $61K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,596 | $61K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 916 | $61K |
| 0004A | <1% | 1,591 | $58K | |
| 72100 | <1% | 2,360 | $58K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 326 | $57K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,730 | $57K |
| 87340 | <1% | 7,764 | $56K | |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | <1% | 77 | $56K |
| 92083 | <1% | 1,149 | $56K | |
| 92550 | <1% | 1,679 | $56K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,956 | $56K |
| 81025 | <1% | 18,601 | $56K | |
| 87800 | <1% | 1,809 | $55K | |
| H0001 | Alcohol and/or drug assessment | <1% | 280 | $52K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 6,520 | $52K |
| 86762 | <1% | 4,013 | $51K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,372 | $51K |
| 99401 | <1% | 2,022 | $49K | |
| 86765 | <1% | 4,389 | $48K | |
| 84439 | <1% | 6,581 | $48K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 205 | $48K |
| 84702 | <1% | 8,967 | $48K | |
| 59425 | <1% | 733 | $47K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 1,295 | $46K |
| 73610 | <1% | 2,412 | $45K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 11,578 | $45K |
| 90670 | <1% | 3,775 | $45K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 67 | $45K |
| 87486 | <1% | 2,695 | $44K | |
| 99386 | <1% | 459 | $44K | |
| 93247 | <1% | 252 | $44K | |
| 73030 | <1% | 2,291 | $42K | |
| 83880 | <1% | 3,184 | $41K | |
| 92133 | <1% | 1,406 | $41K | |
| 73130 | <1% | 2,384 | $41K | |
| 82728 | <1% | 3,876 | $40K | |
| 93017 | <1% | 778 | $40K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,444 | $40K |
| 0003A | <1% | 1,004 | $40K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 84 | $39K |
| 90732 | <1% | 420 | $39K | |
| 85610 | <1% | 12,024 | $38K | |
| 84153 | <1% | 2,765 | $38K | |
| 74019 | <1% | 1,182 | $38K | |
| 92134 | <1% | 1,172 | $37K | |
| 86787 | <1% | 3,777 | $37K | |
| 82951 | <1% | 3,509 | $37K | |
| 92579 | <1% | 662 | $36K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,051 | $36K |
| 86593 | <1% | 10,153 | $35K | |
| 99051 | <1% | 4,327 | $35K | |
| 97165 | <1% | 353 | $35K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 3,382 | $35K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 9,000 | $35K |
| 91320 | <1% | 465 | $34K | |
| 96161 | <1% | 4,518 | $34K | |
| 83020 | <1% | 2,561 | $33K | |
| D0274 | Bitewings - four radiographic images | <1% | 4,712 | $33K |
| 82607 | <1% | 3,161 | $33K | |
| 87581 | <1% | 2,693 | $33K | |
| 82677 | <1% | 1,509 | $32K | |
| 82043 | <1% | 6,549 | $32K | |
| 86735 | <1% | 3,224 | $32K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 205 | $32K |
| 87522 | Neg quan hep c or qual rna | <1% | 787 | $31K |
| 83970 | <1% | 972 | $30K | |
| 12002 | <1% | 143 | $30K | |
| 73110 | <1% | 1,598 | $28K | |
| 73502 | <1% | 1,117 | $28K | |
| 94060 | <1% | 416 | $27K | |
| 86704 | <1% | 3,151 | $27K | |
| 82105 | <1% | 2,235 | $27K | |
| D0272 | Bitewings - two radiographic images | <1% | 5,668 | $27K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 1,079 | $25K |
| 90480 | <1% | 655 | $24K | |
| 82805 | <1% | 3,823 | $24K | |
| 81003 | <1% | 11,605 | $24K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 327 | $23K |
| 80320 | <1% | 9,762 | $23K | |
| 82274 | <1% | 1,757 | $22K | |
| D0330 | Panoramic radiographic image | <1% | 2,171 | $22K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 121 | $22K |
| 94729 | <1% | 387 | $21K | |
| 83550 | <1% | 3,336 | $21K | |
| 0072A | <1% | 506 | $21K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 3,362 | $21K |
| H0049 | Alcohol and/or drug screening | <1% | 310 | $21K |
| 97803 | <1% | 666 | $20K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 107 | $20K |
| 99383 | <1% | 263 | $20K | |
| 90674 | <1% | 1,727 | $20K | |
| 73562 | <1% | 902 | $19K | |
| 90707 | <1% | 1,144 | $19K | |
| 88142 | <1% | 867 | $19K | |
| 94726 | <1% | 284 | $19K | |
| 77080 | <1% | 607 | $19K | |
| 0071A | <1% | 485 | $19K | |
| D1351 | Sealant - per tooth | <1% | 2,167 | $19K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 611 | $18K |
| 83540 | <1% | 3,480 | $17K | |
| 90656 | <1% | 1,341 | $17K | |
| 86336 | <1% | 1,508 | $17K | |
| 90620 | <1% | 616 | $17K | |
| D8670 | Periodic orthodontic treatment visit | <1% | 1,092 | $17K |
| 3074F | <1% | 50,351 | $17K | |
| 92202 | <1% | 1,017 | $16K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 1,393 | $16K |
| 73590 | <1% | 1,151 | $16K | |
| 84207 | <1% | 577 | $16K | |
| 92557 | <1% | 504 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,801 | $15K |
| 96367 | <1% | 402 | $15K | |
| 99423 | <1% | 230 | $15K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 122 | $15K |
| 74018 | <1% | 753 | $15K | |
| 87081 | <1% | 3,144 | $15K | |
| 84703 | <1% | 2,636 | $15K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 1,124 | $14K |
| 85730 | <1% | 7,745 | $14K | |
| 84704 | <1% | 1,114 | $14K | |
| 86003 | <1% | 470 | $14K | |
| 82570 | <1% | 5,261 | $14K | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 25 | $14K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 384 | $13K |
| 90680 | <1% | 2,473 | $13K | |
| 88304 | <1% | 295 | $13K | |
| 11900 | <1% | 104 | $13K | |
| 99384 | <1% | 239 | $13K | |
| 73140 | <1% | 691 | $12K | |
| 84146 | <1% | 621 | $12K | |
| 81002 | <1% | 3,645 | $12K | |
| 88307 | <1% | 138 | $11K | |
| 90716 | <1% | 922 | $11K | |
| 99402 | <1% | 173 | $11K | |
| 73090 | <1% | 866 | $11K | |
| 84154 | <1% | 718 | $11K | |
| 87186 | <1% | 2,184 | $11K | |
| J0515 | Injection, benztropine mesylate, per 1 mg | <1% | 776 | $11K |
| 84484 | <1% | 10,577 | $11K | |
| 0124A | <1% | 291 | $11K | |
| 90744 | <1% | 1,943 | $10K | |
| 90633 | <1% | 1,897 | $10K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 65 | $10K |
| 83735 | <1% | 7,438 | $10K | |
| 87338 | <1% | 895 | $10K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 418 | $10K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 56 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,661 | $9K |
| 99422 | <1% | 184 | $9K | |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 146 | $9K |
| 86592 | <1% | 2,920 | $9K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 190 | $9K |
| 93246 | <1% | 279 | $9K | |
| 29125 | <1% | 86 | $9K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 1,036 | $9K |
| 84402 | <1% | 354 | $9K | |
| 73560 | <1% | 263 | $8K | |
| 82977 | <1% | 1,395 | $8K | |
| 84425 | <1% | 462 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,484 | $8K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 236 | $8K |
| 59426 | <1% | 131 | $8K | |
| 86696 | <1% | 540 | $7K | |
| D1206 | Topical application of fluoride varnish | <1% | 1,342 | $7K |
| 96040 | <1% | 90 | $7K | |
| 83001 | <1% | 407 | $7K | |
| 86038 | <1% | 815 | $7K | |
| D0603 | <1% | 6,824 | $7K | |
| 84156 | <1% | 2,850 | $7K | |
| 90662 | <1% | 424 | $7K | |
| 99451 | <1% | 248 | $7K | |
| 83690 | <1% | 9,967 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,240 | $6K |
| 29130 | <1% | 54 | $6K | |
| 92551 | <1% | 965 | $6K | |
| 96380 | <1% | 392 | $6K | |
| 84100 | <1% | 2,614 | $6K | |
| 58300 | <1% | 62 | $6K | |
| 99406 | <1% | 739 | $6K | |
| 82785 | <1% | 458 | $6K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,819 | $6K |
| 90698 | <1% | 1,342 | $6K | |
| 86695 | <1% | 531 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $6K |
| 84403 | <1% | 209 | $5K | |
| 80165 | <1% | 1,010 | $5K | |
| D3330 | Endodontic therapy, molar tooth (excluding final restoration) | <1% | 44 | $5K |
| 83002 | <1% | 293 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 28 | $5K |
| 76000 | <1% | 26 | $5K | |
| 92201 | <1% | 385 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,333 | $5K |
| 90648 | <1% | 1,121 | $5K | |
| D9430 | <1% | 306 | $5K | |
| 3075F | <1% | 13,290 | $5K | |
| 86140 | <1% | 1,591 | $5K | |
| C1763 | Connective tissue, non-human (includes synthetic) | <1% | 60 | $5K |
| 73120 | <1% | 231 | $5K | |
| 84134 | <1% | 432 | $5K | |
| D0270 | <1% | 970 | $5K | |
| D1330 | <1% | 5,356 | $5K | |
| 86708 | <1% | 406 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,653 | $4K |
| 99382 | <1% | 59 | $4K | |
| 11981 | <1% | 24 | $4K | |
| 88141 | <1% | 266 | $4K | |
| 82746 | <1% | 436 | $4K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 233 | $4K |
| 72070 | <1% | 184 | $4K | |
| D9440 | <1% | 204 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,322 | $4K |
| 73620 | <1% | 168 | $4K | |
| 84590 | <1% | 386 | $4K | |
| 90653 | <1% | 240 | $4K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 80 | $4K |
| 82652 | <1% | 102 | $4K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $4K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,285 | $4K |
| T2022 | Case management, per month | <1% | 96 | $4K |
| 3077F | <1% | 6,148 | $4K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 236 | $4K |
| 92020 | <1% | 150 | $4K | |
| 94727 | <1% | 81 | $3K | |
| 85651 | <1% | 1,534 | $3K | |
| 71100 | <1% | 265 | $3K | |
| 90723 | <1% | 748 | $3K | |
| 83516 | <1% | 293 | $3K | |
| 82550 | <1% | 2,640 | $3K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 48 | $3K |
| 76642 | <1% | 42 | $3K | |
| 84481 | <1% | 266 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,047 | $3K |
| 73080 | <1% | 277 | $3K | |
| D9310 | <1% | 152 | $3K | |
| 82952 | <1% | 486 | $3K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 1,076 | $3K |
| 87517 | <1% | 65 | $3K | |
| 76536 | <1% | 25 | $3K | |
| 87521 | Neg quan hep c or qual rna | <1% | 71 | $3K |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 201 | $3K |
| 86160 | <1% | 170 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,499 | $3K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 14 | $3K |
| 90694 | <1% | 188 | $3K | |
| 86255 | <1% | 275 | $3K | |
| 83883 | <1% | 135 | $2K | |
| 85045 | <1% | 844 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 627 | $2K |
| 90836 | <1% | 25 | $2K | |
| 73070 | <1% | 208 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,688 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,923 | $2K |
| 87070 | <1% | 608 | $2K | |
| 84550 | <1% | 881 | $2K | |
| 93971 | <1% | 38 | $2K | |
| 82248 | <1% | 679 | $2K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 57 | $2K |
| 86235 | <1% | 44 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,032 | $2K |
| 85379 | <1% | 1,654 | $2K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 4,226 | $2K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 220 | $2K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 21 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 325 | $2K |
| 77062 | <1% | 13 | $2K | |
| 90736 | <1% | 13 | $2K | |
| D1354 | <1% | 936 | $2K | |
| 88313 | <1% | 31 | $2K | |
| 0012A | <1% | 97 | $2K | |
| D4341 | <1% | 65 | $2K | |
| 88112 | <1% | 24 | $2K | |
| 73600 | <1% | 103 | $2K | |
| 96160 | <1% | 171 | $2K | |
| 92227 | <1% | 105 | $2K | |
| 73552 | <1% | 147 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 902 | $2K |
| 73060 | <1% | 151 | $2K | |
| 90710 | <1% | 297 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,666 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,524 | $2K |
| 90681 | <1% | 190 | $1K | |
| 82948 | <1% | 525 | $1K | |
| 0011A | <1% | 100 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 863 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,060 | $1K |
| 11056 | <1% | 13 | $1K | |
| 72190 | <1% | 74 | $1K | |
| 83605 | <1% | 1,413 | $1K | |
| 92002 | <1% | 14 | $1K | |
| 97014 | <1% | 65 | $1K | |
| 0081A | <1% | 33 | $1K | |
| 86376 | <1% | 86 | $1K | |
| 90700 | <1% | 216 | $1K | |
| 93226 | <1% | 26 | $1K | |
| 80178 | <1% | 375 | $1K | |
| 96376 | <1% | 1,118 | $1K | |
| 86705 | <1% | 147 | $1K | |
| 82784 | <1% | 60 | $997.67 | |
| 82010 | <1% | 1,321 | $974.49 | |
| 86141 | <1% | 134 | $962.24 | |
| 86225 | <1% | 98 | $954.14 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 40 | $925.10 |
| 83615 | <1% | 314 | $921.37 | |
| 11055 | <1% | 12 | $917.84 | |
| 88300 | <1% | 74 | $915.80 | |
| 74022 | <1% | 67 | $901.18 | |
| 99173 | <1% | 573 | $874.48 | |
| 97168 | <1% | 13 | $833.29 | |
| 82803 | <1% | 495 | $821.16 | |
| 99397 | <1% | 25 | $809.72 | |
| 90696 | <1% | 205 | $772.21 | |
| 83525 | <1% | 57 | $766.86 | |
| 82670 | <1% | 28 | $760.82 | |
| D0191 | <1% | 712 | $757.48 | |
| D9990 | <1% | 74 | $755.50 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 222 | $739.36 |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 17 | $735.85 |
| 86430 | <1% | 157 | $729.03 | |
| 82172 | <1% | 39 | $708.83 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 882 | $703.61 |
| 90672 | <1% | 191 | $701.59 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,928 | $699.87 |
| 90714 | <1% | 52 | $675.25 | |
| 83010 | <1% | 57 | $670.55 | |
| 82947 | <1% | 163 | $664.85 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,657 | $651.47 |
| 0031A | <1% | 18 | $646.67 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 7,529 | $637.59 |
| 92226 | <1% | 29 | $636.25 | |
| 93325 | <1% | 28 | $604.47 | |
| 81243 | <1% | 12 | $587.17 | |
| 80346 | <1% | 165 | $570.44 | |
| 0502F | <1% | 313 | $557.99 | |
| 94010 | <1% | 12 | $557.06 | |
| 97164 | <1% | 12 | $549.31 | |
| 86580 | <1% | 85 | $534.25 | |
| 90685 | <1% | 232 | $525.20 | |
| 90660 | <1% | 64 | $510.43 | |
| 96368 | <1% | 65 | $505.68 | |
| 90474 | <1% | 235 | $493.42 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,050 | $483.22 |
| D1320 | <1% | 72 | $472.00 | |
| 99429 | <1% | 157 | $467.50 | |
| 93307 | <1% | 69 | $464.22 | |
| 82247 | <1% | 107 | $456.09 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 473 | $456.08 |
| 82239 | <1% | 30 | $441.23 | |
| 82731 | <1% | 27 | $439.59 | |
| 0082A | <1% | 14 | $437.35 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,585 | $432.19 |
| 0074A | <1% | 12 | $426.30 | |
| 76820 | <1% | 19 | $420.30 | |
| 83718 | <1% | 195 | $418.85 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 85 | $402.77 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 5,874 | $402.13 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,046 | $394.04 |
| D8660 | <1% | 16 | $391.50 | |
| 85018 | <1% | 191 | $382.39 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 323 | $368.03 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 17 | $364.22 |
| 85014 | <1% | 180 | $355.08 | |
| 85307 | <1% | 26 | $352.91 | |
| 97018 | <1% | 40 | $346.21 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 12 | $343.34 |
| 81015 | <1% | 126 | $341.40 | |
| 91318 | <1% | 16 | $336.38 | |
| 73100 | <1% | 12 | $331.27 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 510 | $323.72 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 787 | $321.00 |
| 84478 | <1% | 194 | $316.08 | |
| 82465 | <1% | 217 | $311.33 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 499 | $309.76 |
| D0160 | <1% | 13 | $302.20 | |
| 87420 | <1% | 158 | $302.12 | |
| 87205 | <1% | 156 | $301.26 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 12 | $295.19 |
| 90678 | <1% | 14 | $284.74 | |
| 87075 | <1% | 63 | $268.20 | |
| G0008 | Administration of influenza virus vaccine | <1% | 596 | $259.81 |
| 85384 | <1% | 93 | $250.21 | |
| 1159F | <1% | 5,332 | $243.29 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 57 | $229.47 |
| 82150 | <1% | 258 | $226.61 | |
| 87400 | <1% | 39 | $224.46 | |
| 90473 | <1% | 120 | $220.85 | |
| 72040 | <1% | 13 | $210.12 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 199 | $210.09 |
| 73660 | <1% | 12 | $206.43 | |
| 80349 | <1% | 19 | $204.16 | |
| 1126F | <1% | 52 | $203.76 | |
| 85660 | <1% | 43 | $197.21 | |
| 99152 | <1% | 14 | $192.40 | |
| 3078F | <1% | 53,654 | $188.76 | |
| 84132 | <1% | 65 | $178.26 | |
| 85306 | <1% | 12 | $162.38 | |
| 85303 | <1% | 13 | $161.90 | |
| 94761 | <1% | 52 | $157.60 | |
| 82103 | <1% | 12 | $156.68 | |
| 90381 | <1% | 48 | $151.50 | |
| 3079F | <1% | 14,284 | $142.64 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 49 | $139.57 |
| 85300 | <1% | 14 | $138.69 | |
| 99446 | <1% | 12 | $131.23 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,424 | $130.64 |
| 86880 | <1% | 20 | $129.16 | |
| 85305 | <1% | 12 | $123.06 | |
| 84436 | <1% | 116 | $119.69 | |
| 90671 | <1% | 23 | $107.99 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 128 | $100.33 |
| 84112 | <1% | 26 | $94.27 | |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 69 | $84.04 |
| 91319 | <1% | 12 | $77.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 30 | $74.38 |
| 82272 | <1% | 43 | $68.97 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 154 | $55.74 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 12 | $51.66 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 35 | $49.66 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 66 | $49.60 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 13 | $48.81 |
| 87040 | <1% | 59 | $48.36 | |
| 87088 | <1% | 231 | $48.06 | |
| 84460 | <1% | 16 | $44.49 | |
| 82397 | <1% | 18 | $29.18 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 25 | $29.09 |
| 94760 | <1% | 513 | $25.66 | |
| 92225 | <1% | 266 | $19.66 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 19 | $17.82 |
| 87071 | <1% | 95 | $16.64 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 95 | $15.89 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 42 | $6.77 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 16 | $4.31 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 12 | $0.93 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 17 | $0.20 |
| 1160F | 0% | 3,639 | $0.00 | |
| 99499 | 0% | 4,665 | $0.00 | |
| D0190 | 0% | 781 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 31 | $0.00 |
| 2022F | 0% | 69 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 444 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 45 | $0.00 |
| 99080 | 0% | 1,575 | $0.00 | |
| 99195 | 0% | 158 | $0.00 | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | 0% | 172 | $0.00 |
| 99408 | 0% | 32 | $0.00 | |
| 3725F | 0% | 36 | $0.00 | |
| G0445 | High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes | 0% | 33 | $0.00 |
| 48510 | 0% | 750 | $0.00 | |
| 3080F | 0% | 2,096 | $0.00 | |
| 4293F | 0% | 102 | $0.00 | |
| 80050 | General health panel | 0% | 590 | $0.00 |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 12 | $0.00 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 439 | $0.00 |
| 3044F | 0% | 13 | $0.00 | |
| 1170F | 0% | 141 | $0.00 | |
| 86707 | 0% | 25 | $0.00 | |
| 1220F | 0% | 288 | $0.00 | |
| D1310 | 0% | 330 | $0.00 | |
| 84479 | 0% | 14 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 76 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 12 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 21 | $0.00 |
| 87350 | 0% | 25 | $0.00 | |
| 90647 | 0% | 37 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.